The FDA approved AbbVie's new Parkinson's drug, while WuXi Biologics and Biocon secured key regulatory clearances for manufacturing and international distribution. However, legal troubles escalated for the sector as Florida sued insulin makers and generic manufacturers settled massive price-fixing claims for $96 million. Additionally, new federal Medicaid work requirements are projected to drop 7.5 million people from insurance coverage.
01Company specific
FDA Approves AbbVie Next-Gen Parkinson's Therapy
The US Food and Drug Administration approved AbbVie's once-daily Parkinson's pill Juvmo, known generically as tavapadon, for adult patients. AbbVie acquired the selective dopamine D1/D5 receptor agonist through its $8.7 billion purchase of Cerevel Therapeutics in 2023. The regulatory clearance relies on data from the late-stage TEMPO clinical programme. In the TEMPO-2 trial of 304 early-stage patients, tavapadon delivered greater improvements in motor function and daily activities than placebo. A second study, TEMPO-3, tested 507 participants already taking levodopa and found the drug added about 1.1 hours of daily good-on time and reduced off time by nearly an hour. Common side effects in the trials included nausea, dizziness, headache, and, in TEMPO-3, dyskinesia and orthostatic hypotension. More than 11 million people live with Parkinson's worldwide, and AbbVie continues to target over $5 billion in combined sales for its in the . Citi analysts expect the drug to launch in the third quarter of 2026, though uptake will likely depend on coverage negotiations.
Generic Drug Manufacturers Settle Antitrust Claims for $96 Million
Six manufacturers agreed to pay more than $96 million to settle claims brought by a coalition of 48 attorneys general. The settlement resolves allegations that the companies coordinated prices and rigged bids on more than 100 generic drugs between May 1, 2009, and December 31, 2019. The defendants named in the settlements include Apotex Corp., Heritage Pharmaceuticals Inc., Emcure Pharmaceuticals Ltd., Bausch Health US LLC, Bausch Health Americas Inc., Lannett Company Inc., and Glenmark Pharmaceuticals Inc. USA. Court documents allege that executives met at industry events and social gatherings to coordinate price increases, which in some cases topped 1,000 percent for everyday medications such as Digoxin. The U.S. District Court for the District of Connecticut granted preliminary approval to the distribution plan under case number 3:16-cv-02056. Individual consumers and businesses that purchased qualifying generic prescriptions in participating jurisdictions during the decade-long period are eligible to submit claims. Out of the total fund, the Glenmark settlement alone allocates roughly $20.7 million for consumer distribution and about $8.9 million for administration and litigation costs. Claimants have until March 8, 2027, to file documentation through the official administrator portal at AGGenericDrugs.com. All six settling companies deny wrongdoing, resolving the litigation as a business decision to avoid further costs.
State of Florida Files Antitrust Lawsuit Against Eli Lilly, Sanofi, and CVS
The State of Florida filed an lawsuit against Eli Lilly, Novo Nordisk, and Sanofi on September 22, 2026, alleging that the major drug manufacturers colluded with pharmacy benefit managers to inflate diabetes medication prices. The complaint, lodged in Florida's 11th Judicial Circuit in Miami-Dade County by Attorney General James Uthmeier, also names CVS Caremark, Express Scripts, and OptumRx, alongside rebate aggregators Zinc, Ascent, and Emisar, and UnitedHealthcare Insurance. The defendant manufacturers supply more than 90% of the world's insulin, while the targeted pharmacy benefit managers process about 80% of U.S. prescriptions. According to the state's filing, drugmakers deliberately drove up published list prices for insulin and medications like Ozempic, Trulicity, Victoza, and Soliqua, subsequently returning substantial rebates to the benefit managers to secure preferred formulary placement. Uthmeier cited previous executive testimony revealing that Eli Lilly returns roughly $210, or about 75%, of a $280 vial of Humalog to benefit managers and aggregators. Uninsured patients, those meeting deductibles, and consumers on percentage-based coinsurance absorb these elevated sticker prices rather than the negotiated net prices, leaving approximately 2.3 million Florida adults with diabetes vulnerable to heavy financial strain. The lawsuit brings two counts under the Florida Deceptive and Unfair Trade Practices Act and one count under the Florida Antitrust Act, seeking permanent injunctions, civil penalties, and damages.
GOP States Set Strict Work Rules as New Medicaid Regulations Take Effect
New federal work requirements taking effect in January will result in 7.5 million fewer people having health insurance and save the federal government $887 billion over the next decade, according to Congressional Budget Office estimates cited by Fortune. The mandate applies to up to 20 million lower-income adults without children who are enrolled in Medicaid through an optional expansion across 40 states and the District of Columbia. Beneficiaries must work or volunteer at least 80 hours each month or maintain half-time student status to qualify for coverage. While federal rules allow states to accept a recipient's word for medical exemptions during the first year, at least six states are barring self-attestation immediately. Arkansas, Idaho, Indiana, New Hampshire, North Carolina and Ohio require formal documentary evidence of medical frailty starting next year. Democrats in 25 states are currently suing over the harsher rules, arguing that requiring physician documentation creates an insurmountable barrier for applicants who cannot afford a doctor visit. Supporters of the stricter approach argue that self-attestation encourages fraud and inflates program costs. States will be permitted to accept self-attestation just once per enrollment period beginning in 2028, after which documentation must be provided every 12 months.
Biocon Malaysia Secures UK MHRA Approval for Insulin Fill-Finish Unit
Biocon secured UK Medicines and Healthcare products Regulatory Agency approval for a new drug product fill-finish unit covering Semglee insulin at its manufacturing facility in Malaysia. The clearance enables aseptic packaging and final delivery of Semglee to the UK market, following prior European Medicines Agency approvals for the same unit. The dual regulatory clearances complete Biocon's European framework for its Malaysia insulin hub. The facility supports a exceeding 30 products, including Aflibercept, trastuzumab, and pegfilgrastim. The approvals position the Malaysia hub as a commercially viable source for the combined EU and UK biosimilar markets.
WuXi cleared a two-week unannounced good manufacturing practice inspection at its Wuxi Mashan manufacturing site. The routine audit covered multiple approved products including monoclonal antibodies, bispecific antibodies, fusion proteins, and enzyme products to reinforce commercial supply reliability for the U.S. market. Over the past 13 years, the site achieved a 100 percent success rate across more than 600 regulatory and client audits while supporting the global launch of over 20 biologics. As of the end of June 2026, the company successfully passed 49 regulatory inspections, including 22 conducted by the FDA and EMA, and secured 166 facility licence approvals. The company also passed more than 2,000 GMP quality audits by global clients, including over 280 audits by EU Qualified Persons. Currently, the company operates 26 drug substance facilities and 19 drug product facilities within its global network, supporting 1,064 integrated client projects as of June 30, 2026. These projects include 78 in and 28 in commercial manufacturing.
Regulatory wins for new treatments contrast sharply with severe legal liabilities over pricing collusions and sweeping Medicaid roll reductions. The key open question is whether impending policy shifts and court settlements will permanently erode profit margins across generic and essential drug markets.
This, every morning.
SuMarket writes Healthcare and Pharmaceutical Sector every morning, along with every other section of the market and the companies and topics you follow. Free to read.